Higher dose of Crohn's drug shows promise for tough cases
NCT ID NCT00805766
First seen Jan 09, 2026 · Last updated May 03, 2026 · Updated 14 times
Summary
This study looked at whether a higher dose (10 mg/kg) of the drug TA-650 (also known as infliximab) could help people with Crohn's disease who were not getting enough benefit from the standard dose. The 39 participants received the higher dose every 8 weeks, and researchers tracked their symptoms using a standard scoring system. The goal was to see if symptoms improved enough to make the higher dose a useful option for managing this chronic condition.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHN'S DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational site
Hokkaido, Japan
-
Investigational site
Kansai, Japan
-
Investigational site
Kanto, Japan
-
Investigational site
Kyushu, Japan
Conditions
Explore the condition pages connected to this study.